

Repurchase of shares in Synact Pharma AB

SynAct Pharma AB (publ) ("SynAct" or the "Company") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the Company has repurchased a total of 212,307 own shares as part of the share buyback program initiated by the Board of Directors.

The executed buybacks form part of the share buyback program of maximum SEK 5 million resolved by the Board of Directors of SynAct on 9 January 2026, based on the authorization from the extraordinary general meeting on 27 November 2025, which was announced on the same day. The share buyback program, which runs between 12 January 2026 and no later than 28 February 2026, is being carried out in accordance with the EU Market Abuse Regulation ("MAR") and the European Commission's Delegated Regulation 2016/1052 (the "Safe Harbour Regulation").

Shares in SynAct (ISIN: SE0008241491) have been repurchased as follows:

Date	Aggregated daily volume (number of shares)	Weighted average share price per day (SEK)	Total daily transaction value (SEK)
2026-01-12	32 187	22,972	739 406
2026-01-13	28 327	23,322	660 639
2026-01-14	30 039	23,725	712 675
2026-01-15	29 252	24,103	705 049
2026-01-16	30 420	23,879	726 387
2026-01-19	9 750	23,128	225 497
2026-01-20	21 022	22,838	480 092
2026-01-21	27 710	22,275	617 235
2026-01-22	500	21,900	10 950
2026-02-12	3 100	18,881	58 532

All acquisitions have been made on Nasdaq Stockholm by Mangold Fondkommission AB on behalf of SynAct. The total number of shares in SynAct, including own shares, amounts to 53,330,243. As of the date of this press release, SynAct's holding of own shares amounts to 212,307.

For further information, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB Phone: + 45 2844 7567

E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: <https://synactpharma.com/>.

This information is information that SynAct Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-17 17:30 CET.

Attachments

[Repurchase of shares in Synact Pharma AB](#)